News Archives
2005
September 21, Adlyfe's Blood Diagnostic Technology Presented at the World Health Organization Consultation in Geneva. More...
September 15, Adlyfe diagnostic technology described in Genetic Engineering News article, "Prion Disease Mechanisms and Activation: Finding Faulty Proteins." More...
September 7, Animal and Human Health Agency Awards $650,000 to Develop Adlyfe Blood Test Related to Misfolded Protein Diseases Such as Sheep Scrapie and Mad Cow Disease. More...
July 5, Adlyfe Develops Blood Test to Provide Effective Way to Detect Mad Cow and Related Misfolded Protein Diseases. More...
June 8, Adlyfe is awarded $1.75M R&D contract by the Department of Defense for rapid development of stabilized platelets for infusible clinical applications.
June 3, In the 2005 #21 edition of the America's Blood Centers Newsletter a report from the May Health and Human Services Committee on Blood Safety and Availability, Adlyfe's diagnostic assay was described...(More)
May 1, Alan Rudolph, CEO and President of Adlyfe, invited to Annual Japan Blood Society meetings in Tokyo Japan June 5-8 to present Adlyfe's blood diagnostic technology for misfolded prion proteins. (please see abstract)
April 14, Adlyfe selected to present at The Mid-Atlantic Venture Association's BioConnection 2005, on May 31st, in Baltimore, Maryland. BioConnection 2005 is the premier venture event showcasing the region's most fundable healthcare companies. "The investors who come to BioConnection 2005 will see some of the most fundable life sciences companies in the market today," said James Barrett, Co-Chair of BioConnection 2005 and General Partner of New Enterprise Associates. "These presenting companies demonstrate the continued strength and high quality of the entrepreneurs who are selected to participate in one of the venture industry's premier venture fairs." For more information, please visit www.mava.org
February 15, Adlyfe's Dr. Cindy Orser presents "A Rapid Pre-Symptomatic Diagnostic Test for PrPsc in Tissue and Blood Using Conformationally Sensitive PrP Peptide Ligands" at the CHI 9th Annual Transmissible Spongiform Encephalopathies International Meeting in McLean Virginia http://www.healthtech.com/2005/tse/index.ASP
February 3, Adlyfe selected by The Washington DC Technology Council as one of 10 high growth companies to present at the Early Stage Capital Forum on February 11 at the Ronald Reagan International Trade Center www.dctechcouncil.org
January 14, Adlyfe submission to the Wound Healing Society 15th Annual Meeting in Chicago, Illinois, May 18-21, 2005 titled: "WOUND HEALING PROPERTIES OF RECONSTITUTED FREEZE-DRIED PLATELETS" selected as a finalist for the Blue Ribbon Industrial Research and Development Award
2004
December 14, Adlyfe adds Richard Becker (CEO, GW Hospital), John Preston (Former Managing Director of Merck), and Derek Woods, (Senior Executive, VP Becton-Dickinson) to its Board of Directors
November 17, Adlyfe awarded Department of the Army OSD Phase 1 SBIR for the development of hemostatic wound dressing incorporating stabilized platelets
October 1, Adlyfe awarded R&D subcontract from Geo-Centers, Inc. to drug delivery applications using platelet derived membranes
May 27, NIDDK award SBIR Phase I to Adlyfe for exploration of loading technologies for platelet membranes
February 1, NHLBI SBIR Phase II contract to develop new peptide ligands for detection of Prion Disease is novated to Adlyfe from Arete
January 17, Cindy Orser, PhD, joins Adlyfe as Director of Research and Development
January 17, Adlyfe acquires exclusive license for Protein Misfolded Ligands for blood related tests for neurodegenerative disease from Arete Associates
2003
December 1, Adlyfe occupies 5,000 sq. ft. biotech facility at 9430 Key West Avenue, Rockville, Maryland
November 7, Alan S. Rudolph, PhD, MBA joins Adlyfe as Executive Vice President and Chief Technology Officer
October 1, Adlyfe enters joint venture with Oregon Freeze-Dry, DriMedica, for the manufacturing and sales of platelet derivative membrane products.
July 1, Adlyfe is awarded $2.5M R&D contract by the Defense Advanced Research Projects Agency for development of advanced wound healing and rapid hemostats based on platelet derivative membranes
|
